Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQSGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the year.
Shares of Air Products and Chemicals, Inc. (NYSEAPD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.
Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold as part of a profit-sharing agreement with Incyte, which saw net product sales of $92 million in 2023. MorphoSys also is developing Pelabresib, an inhibitor of proteins involved in the development and progression of myelofibrosis.
Shares of Super Micro Computer, Inc. (NASDAQSMCI) rose sharply in pre-market trading after the company announced updated financial guidance for the second-quarter, which surpassed its previou
Shares of TransCode Therapeutics, Inc. (NASDAQRNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.
